Results 51 to 60 of about 319,040 (312)

Low concentrations of recombinant activated factor VII normalize coagulation patterns by reversing the changes in viscoelastic testing parameters induced by abelacimab in vitro

Research and Practice in Thrombosis and Haemostasis
Background: Low doses of recombinant activated factor (F)VII (rFVIIa), used to manage bleeding in patients with severe FXI deficiency, have been proposed to bypass effects of the FXI/FXIa inhibitor abelacimab.
Yasser Khder, Serge Côté, Klaus Peter Hoffmann, Debra Freedholm, Dan Bloomfield, Jean M. Connors   +5 more
doaj   +1 more source

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi, Daisuke Katagiri, Takeyuki Watadani, Shunichi Matsuda, Hiroshi Kaneko, Noritoshi Arai   +5 more
wiley   +1 more source

Half-dose may be equivalent to full-dose anticoagulants in preventing venous thromboembolism after primary total joint arthroplasty: a single center comparative retrospective cohort study

Frontiers in Pharmacology
BackgroundThe optimal anticoagulant administration for deep vein thrombosis (DVT) prevention following total joint arthroplasty (TJA) remains controversial.
Yinghao Wang, Yinghao Wang, Zhixin Liao, Zhixin Liao, Zongke Zhou, Zongke Zhou, Haoyang Wang, Haoyang Wang   +7 more
doaj   +1 more source

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundWe studied the concomitant use of single antiplatelet therapy (SAPT) on the efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF). Methods and ResultsENGAGE AF‐TIMI 48 was a randomized trial that compared 2
Haiyan Xu, Christian T. Ruff, Robert P. Giugliano, Sabina A. Murphy, Francesco Nordio, Indravadan Patel, Minggao Shi, Michele Mercuri, Elliott M. Antman, Eugene Braunwald   +9 more
doaj   +1 more source

Investigation on the incidence of adverse reactions of subcutaneous anticoagulant injection and its influencing factors (抗凝剂皮下注射不良反应发生率现况调查及其影响因素研究)

中西医结合护理, 2021
Objective To investigate the incidence and influencing factors of adverse reactions of injection site after subcutaneous anticoagulant injection under the guidance of evidence-based nursingMethods Using the convenient sampling method, 608 patients with ...
DAI Lili (代莉莉), DUAN Yanqin (段艳芹), ZHANG Mei (张梅), ZHU Suqin (朱素芹), CHEN Juan (陈娟), SUN Yuling (孙玉玲)   +5 more
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Danaparoid—Consensus Recommendations on Its Clinical Use

Pharmaceuticals
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis.
Rupert M. Bauersachs, Edelgard Lindhoff-Last, Robert Klamroth, Andreas Koster, Marc Schindewolf, Harry Magnani   +5 more
doaj   +1 more source

Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI

Медицинский совет, 2019
This article is devoted to the problem of combined antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS).
A. D. Erlich
doaj   +1 more source

Comparison of Novel Oral Anticoagulants and Vitamin K Antagonists in Patients With Cerebral Venous Sinus Thrombosis on Efficacy and Safety: A Systematic Review

Frontiers in Neurology, 2020
Vitamin K antagonists (VKAs) are guideline-suggested subacute anticoagulants for cerebral venous sinus thrombosis (CVST), although there is potential hemorrhage risk in clinical use. In the last decade, novel oral anticoagulants (NOACs) have been applied
Hongjie Li, Meiling Yao, Songjie Liao, Jingyan Chen, Jian Yu   +4 more
doaj   +1 more source

Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis? [PDF]

, 2019
Porto sinusoidal vascular liver disease (PSVD) and portal vein thrombosis (PVT) are distinct vascular liver diseases characterized, respectively, by an intrahepatic and a prehepatic obstacle to the flow in the liver portal system. PVT may also occur as a
D'Amati, G., Gioia, S., Nardelli, S., Ridola, L., Riggio, O.   +4 more
core   +1 more source